|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,359.00 JPY | -0.72% |
|
0.00% | +10.84% |
| 07-08 | Takeda Pharmaceutical Completes Share Issuance, Disposal Under Incentive Plan | MT |
| 07-02 | Asian Equities Traded in the US as American Depositary Receipts Surge in Thursday Trading | MT |
| Fiscal Period: March | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 2.87 | 2.85 | 2.12 | 2.4 | 2.55 | |||||
Return on Total Capital | 3.61 | 3.57 | 2.57 | 2.84 | 3.05 | |||||
Return On Equity % | 4.24 | 5.27 | 2.12 | 1.52 | -2.12 | |||||
Return on Common Equity | 4.24 | 5.27 | 2.11 | 1.52 | -2.12 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 68.41 | 68.88 | 66.43 | 65.7 | 64.06 | |||||
SG&A Margin | 24.83 | 24.76 | 24.72 | 24.11 | 24.06 | |||||
EBITDA Margin % | 31.17 | 30.06 | 26.68 | 26.92 | 27.44 | |||||
EBITA Margin % | 28.53 | 27.44 | 23.81 | 24.26 | 24.69 | |||||
EBIT Margin % | 16.8 | 15.39 | 11.57 | 12.29 | 13.49 | |||||
Income From Continuing Operations Margin % | 6.45 | 7.87 | 3.38 | 2.36 | -3.38 | |||||
Net Income Margin % | 6.45 | 7.87 | 3.38 | 2.36 | -3.38 | |||||
Net Avail. For Common Margin % | 6.45 | 7.87 | 3.38 | 2.36 | -3.38 | |||||
Normalized Net Income Margin | 7.6 | 7.67 | 5.14 | 5.78 | 6.48 | |||||
Levered Free Cash Flow Margin | 26.02 | 11.93 | 2.71 | 16.06 | 14.93 | |||||
Unlevered Free Cash Flow Margin | 28.17 | 13.74 | 4.4 | 17.84 | 16.99 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.27 | 0.3 | 0.29 | 0.31 | 0.3 | |||||
Fixed Assets Turnover | 2.35 | 2.46 | 2.32 | 2.32 | 2.2 | |||||
Receivables Turnover (Average Receivables) | 5.39 | 6.75 | 7.18 | 7.25 | 6.17 | |||||
Inventory Turnover (Average Inventory) | 1.4 | 1.36 | 1.3 | 1.29 | 1.24 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.21 | 0.97 | 1.11 | 1.01 | 1.09 | |||||
Quick Ratio | 0.73 | 0.49 | 0.5 | 0.44 | 0.52 | |||||
Operating Cash Flow to Current Liabilities | 0.52 | 0.39 | 0.31 | 0.42 | 0.37 | |||||
Days Sales Outstanding (Average Receivables) | 67.75 | 54.06 | 50.98 | 50.34 | 59.11 | |||||
Days Outstanding Inventory (Average Inventory) | 260.17 | 267.91 | 280.77 | 281.89 | 294.62 | |||||
Average Days Payable Outstanding | 78.56 | 79.42 | 69.38 | 72.64 | 64.21 | |||||
Cash Conversion Cycle (Average Days) | 249.35 | 242.54 | 262.38 | 259.6 | 289.52 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 84.64 | 76.51 | 75.11 | 73.37 | 73.7 | |||||
Total Debt / Total Capital | 45.84 | 43.34 | 42.89 | 42.32 | 42.43 | |||||
LT Debt/Equity | 80.1 | 70.22 | 69.15 | 64.52 | 65.93 | |||||
Long-Term Debt / Total Capital | 43.38 | 39.79 | 39.49 | 37.22 | 37.95 | |||||
Total Liabilities / Total Assets | 56.87 | 54.47 | 51.86 | 51.32 | 52.1 | |||||
EBIT / Interest Expense | 4.9 | 5.3 | 4.27 | 4.31 | 4.1 | |||||
EBITDA / Interest Expense | 9.43 | 10.76 | 10.3 | 9.84 | 8.68 | |||||
(EBITDA - Capex) / Interest Expense | 8.42 | 9.56 | 8.78 | 8.3 | 7.5 | |||||
Total Debt / EBITDA | 4.17 | 3.86 | 4.6 | 3.96 | 4.26 | |||||
Net Debt / EBITDA | 3.43 | 3.44 | 4.21 | 3.66 | 3.79 | |||||
Total Debt / (EBITDA - Capex) | 4.67 | 4.35 | 5.39 | 4.7 | 4.93 | |||||
Net Debt / (EBITDA - Capex) | 3.84 | 3.87 | 4.94 | 4.34 | 4.4 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 11.61 | 12.85 | 5.87 | 7.45 | -1.66 | |||||
Gross Profit, 1 Yr. Growth % | 11.79 | 13.62 | 2.09 | 6.28 | -4.11 | |||||
EBITDA, 1 Yr. Growth % | 21.34 | 8.78 | -6.03 | 7.81 | 0.24 | |||||
EBITA, 1 Yr. Growth % | 22.86 | 8.47 | -8.13 | 8.82 | 0.06 | |||||
EBIT, 1 Yr. Growth % | 41.54 | 3.27 | -20.4 | 12.71 | 7.98 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -38.81 | 37.74 | -54.52 | -25 | -240.67 | |||||
Net Income, 1 Yr. Growth % | -38.82 | 37.8 | -54.56 | -25.08 | -241.2 | |||||
Normalized Net Income, 1 Yr. Growth % | 54.72 | 12.83 | -29.04 | 18.83 | 10.14 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -38.96 | 38.44 | -54.86 | -26.25 | -243.91 | |||||
Accounts Receivable, 1 Yr. Growth % | -12.72 | -6.82 | 6.43 | 6.36 | 24.04 | |||||
Inventory, 1 Yr. Growth % | 13.17 | 15.62 | 22.65 | 0.62 | 14.73 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 8.86 | 6.85 | 17.65 | -1.08 | 7.74 | |||||
Total Assets, 1 Yr. Growth % | 2.06 | 5.92 | 8.25 | -5.7 | 8.87 | |||||
Tangible Book Value, 1 Yr. Growth % | -8.18 | 6.41 | -10.89 | -16.2 | -10.98 | |||||
Common Equity, 1 Yr. Growth % | 9.86 | 11.81 | 14.47 | -4.65 | 7.13 | |||||
Cash From Operations, 1 Yr. Growth % | 11.1 | -13 | -26.69 | 47.58 | -1.49 | |||||
Capital Expenditures, 1 Yr. Growth % | 10.83 | 14.12 | 24.71 | 14.47 | -12.35 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 18.53 | -48.31 | -75.95 | 516.06 | -8.54 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 16.17 | -44.97 | -66.1 | 326.66 | -6.34 | |||||
Dividend Per Share, 1 Yr. Growth % | 0 | 0 | 4.44 | 4.26 | 2.04 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 4.14 | 12.23 | 9.3 | 6.66 | 2.8 | |||||
Gross Profit, 2 Yr. CAGR % | 6.05 | 12.7 | 7.7 | 4.16 | 0.95 | |||||
EBITDA, 2 Yr. CAGR % | 12.41 | 10.94 | -1.94 | -2 | 0.23 | |||||
EBITA, 2 Yr. CAGR % | 85.27 | 61.44 | 30.08 | 33.94 | 48.77 | |||||
EBIT, 2 Yr. CAGR % | 42.15 | 20.88 | -9.34 | -4.69 | 9.97 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 127.96 | -8.2 | -20.85 | -41.6 | 2.71 | |||||
Net Income, 2 Yr. CAGR % | 128.04 | -8.18 | -20.87 | -41.65 | 2.85 | |||||
Normalized Net Income, 2 Yr. CAGR % | 78.27 | 32.66 | -10.41 | -7.36 | 14.02 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 127.23 | -8.07 | -20.95 | -42.3 | 3.02 | |||||
Accounts Receivable, 2 Yr. CAGR % | -4.05 | -9.81 | -0.41 | 6.4 | 14.86 | |||||
Inventory, 2 Yr. CAGR % | 5.98 | 14.39 | 19.08 | 11.09 | 7.44 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 6.85 | 7.85 | 12.12 | 7.88 | 3.24 | |||||
Total Assets, 2 Yr. CAGR % | 1.38 | 3.97 | 7.08 | 1.04 | 1.32 | |||||
Tangible Book Value, 2 Yr. CAGR % | -14.27 | -1.16 | -2.63 | -13.59 | -13.63 | |||||
Common Equity, 2 Yr. CAGR % | 9.69 | 10.83 | 13.13 | 4.47 | 1.07 | |||||
Cash From Operations, 2 Yr. CAGR % | 29.5 | -1.68 | -20.14 | 4.01 | 20.57 | |||||
Capital Expenditures, 2 Yr. CAGR % | -1.52 | 12.46 | 19.3 | 19.48 | 0.17 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -0.04 | -21.72 | -64.74 | 23.76 | 135.45 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -0.85 | -20.04 | -56.81 | 21.52 | 98.89 | |||||
Dividend Per Share, 2 Yr. CAGR % | 0 | 0 | 2.2 | 4.35 | 3.14 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 19.39 | 6.96 | 10.06 | 8.68 | 3.81 | |||||
Gross Profit, 3 Yr. CAGR % | 19.09 | 8.52 | 9.05 | 7.23 | 1.33 | |||||
EBITDA, 3 Yr. CAGR % | 33.82 | 11.2 | 4.97 | 1.39 | -1.26 | |||||
EBITA, 3 Yr. CAGR % | 67.54 | 55.02 | 33.78 | 22.82 | 21.54 | |||||
EBIT, 3 Yr. CAGR % | 40.42 | 27.83 | 5.17 | -2.11 | -0.64 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 19.44 | 92.72 | -27.36 | -22.26 | -21.71 | |||||
Net Income, 3 Yr. CAGR % | 19.39 | 92.79 | -27.37 | -22.3 | -21.66 | |||||
Normalized Net Income, 3 Yr. CAGR % | 50.84 | 53.5 | 7.69 | -0.99 | -1.86 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 1.42 | 92.63 | -27.47 | -22.76 | -21.75 | |||||
Accounts Receivable, 3 Yr. CAGR % | -2.08 | -4.98 | -4.7 | 1.8 | 11.98 | |||||
Inventory, 3 Yr. CAGR % | -2.47 | 9.1 | 17.08 | 12.58 | 12.29 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 5.92 | 6.85 | 11.03 | 7.53 | 7.83 | |||||
Total Assets, 3 Yr. CAGR % | -1.51 | 2.87 | 5.38 | 2.64 | 3.58 | |||||
Tangible Book Value, 3 Yr. CAGR % | -12.6 | -7.87 | -4.51 | -7.38 | -12.73 | |||||
Common Equity, 3 Yr. CAGR % | 3.12 | 10.39 | 12.03 | 6.86 | 5.35 | |||||
Cash From Operations, 3 Yr. CAGR % | 50.65 | 13.42 | -10.85 | -2 | 2.15 | |||||
Capital Expenditures, 3 Yr. CAGR % | 16.64 | 3.44 | 16.41 | 17.67 | 7.76 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 21.5 | -19.75 | -47.18 | -7.49 | 11.89 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 27.26 | -18.51 | -39.93 | -6.68 | 11.41 | |||||
Dividend Per Share, 3 Yr. CAGR % | 0 | 0 | 1.46 | 2.88 | 3.57 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 15.56 | 17.87 | 15.25 | 6.84 | 7.1 | |||||
Gross Profit, 5 Yr. CAGR % | 15.76 | 16.82 | 14.4 | 6.75 | 5.73 | |||||
EBITDA, 5 Yr. CAGR % | 30.24 | 27.45 | 19.64 | 6.97 | 4.68 | |||||
EBITA, 5 Yr. CAGR % | 52.01 | 44.11 | 36.21 | 30.24 | 21.27 | |||||
EBIT, 5 Yr. CAGR % | 36.73 | 28.36 | 17.9 | 13.67 | 7.47 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 14.78 | 11.17 | 1.31 | 19.55 | -16.56 | |||||
Net Income, 5 Yr. CAGR % | 14.89 | 11.15 | 1.28 | 19.53 | -16.53 | |||||
Normalized Net Income, 5 Yr. CAGR % | 30.27 | 30.21 | 22.62 | 25.43 | 10.72 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -0.05 | -3.2 | -8.2 | 18.93 | -16.54 | |||||
Accounts Receivable, 5 Yr. CAGR % | 11.62 | 9.78 | -1.42 | -0.58 | 2.69 | |||||
Inventory, 5 Yr. CAGR % | 30.43 | 35.88 | 5.64 | 9.89 | 13.12 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 24.59 | 25.8 | 8.36 | 7.26 | 7.84 | |||||
Total Assets, 5 Yr. CAGR % | 24.83 | 27.72 | 1.84 | 2.13 | 3.74 | |||||
Tangible Book Value, 5 Yr. CAGR % | 68.3 | 125.82 | -8.74 | -10.2 | -8.27 | |||||
Common Equity, 5 Yr. CAGR % | 24.57 | 26.04 | 7.02 | 7.98 | 7.51 | |||||
Cash From Operations, 5 Yr. CAGR % | 33.86 | 20.93 | 16.88 | 9.56 | 0.6 | |||||
Capital Expenditures, 5 Yr. CAGR % | 14.86 | 15.99 | 17.69 | 9.58 | 9.62 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 27.67 | 11.58 | -25.92 | -4.57 | -3.01 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 29.27 | 14.28 | -17.39 | -4.38 | -2.43 | |||||
Dividend Per Share, 5 Yr. CAGR % | 0 | 0 | 0.87 | 1.72 | 2.13 |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















